Anthony Bergmann Sells 500 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 500 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00. Following the completion of the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at $336,690. The trade was a 4.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Anthony Bergmann also recently made the following trade(s):

• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $30.40 on Friday. The stock’s fifty day moving average price is $30.18 and its two-hundred day moving average price is $28.43. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -13.10 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities analysts predict that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV bought a new position in Capricor Therapeutics during the first quarter worth about $44,000. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $43,000. GoalVest Advisory LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $59,000. Allworth Financial LP raised its position in shares of Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 3,264 shares during the period. Finally, State of Wyoming boosted its stake in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 1,913 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. B. Riley Financial boosted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Roth Mkm reiterated a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Finally, Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.30.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.